Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion

Mantle cell lymphoma (MCL) is a rare and aggressive subtype of non-Hodgkin B-cell lymphoma that presents significant clinical management challenges. Recent advancements in treatment strategies, such as Bruton's tyrosine kinase inhibitors (BTKi), chimeric antigen receptor T-cell (CAR-T) therapy, and chemo-free regimens, have transformed the therapeutic landscape. This expert opinion article, based on insights from 14 experts worldwide, explores the evolving role of autologous stem cell transplantation (ASCT) in MCL management, and the treatment approaches for ASCT-ineligible patients. It discusses the benefits and limitations of emerging therapies, emphasizing personalized treatment approaches to optimize clinical outcomes. Tailoring strategies to individual patient profiles, considering genetic markers, comorbidities, and regional healthcare resources, is crucial. The evolving MCL landscape prioritizes personalized care, with BTKi emerging as an effective first-line option for ineligible ASCT patients and a robust alternative to ASCT. Global collaboration and knowledge sharing are essential to advance MCL treatment and ensure optimal care.

Authors

Institutions

Publication Details

Journal
Leukemia & lymphoma/Leukemia and lymphoma
Published
2026-03-17
DOI
https://doi.org/10.1080/10428194.2026.2640453
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion

Miguel Arturo Pavlovsky, Ashraf Elghandour, Eliza A. Hawkes, Danielle Leão Cordeiro de Farias et al.
Leukemia & lymphoma/Leukemia and lymphoma
Lymphoma Diagnosis and Treatment
article

Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion

Miguel Arturo Pavlovsky, Ashraf Elghandour, Eliza A. Hawkes, Danielle Leão Cordeiro de Farias, Mubarak Al Mansour, João Samuel de Holanda Farias, Haiwen Huang, Fernando Pérez Zincer, Calvin Cheah, Bor Sheng Ko, Zhiming Li, Shin Yeu Ong, Yuqin Song, Won Seog Kim
article en

Abstract

Mantle cell lymphoma (MCL) is a rare and aggressive subtype of non-Hodgkin B-cell lymphoma that presents significant clinical management challenges. Recent advancements in treatment strategies, such as Bruton's tyrosine kinase inhibitors (BTKi), chimeric antigen receptor T-cell (CAR-T) therapy, and chemo-free regimens, have transformed the therapeutic landscape. This expert opinion article, based on insights from 14 experts worldwide, explores the evolving role of autologous stem cell transplantation (ASCT) in MCL management, and the treatment approaches for ASCT-ineligible patients. It discusses the benefits and limitations of emerging therapies, emphasizing personalized treatment approaches to optimize clinical outcomes. Tailoring strategies to individual patient profiles, considering genetic markers, comorbidities, and regional healthcare resources, is crucial. The evolving MCL landscape prioritizes personalized care, with BTKi emerging as an effective first-line option for ineligible ASCT patients and a robust alternative to ASCT. Global collaboration and knowledge sharing are essential to advance MCL treatment and ensure optimal care.

Leukemia & lymphoma/Leukemia and lymphoma
Gaertner (United States) (US), Sun Yat-sen University (CN), National Taiwan University (TW), The University of Western Australia (AU), National Taitung University (TW), King Saud bin Abdulaziz University for Health Sciences (SA), Singapore General Hospital (SG), Samsung Medical Center (KR), Sir Charles Gairdner Hospital (AU), Soochow University (CN), Hospital Erasto Gaertner (BR), Development Fund (NO), Beneficência Portuguesa de São Paulo (BR), Monash Health (AU), National Clinical Research (US), National Taiwan University Hospital (TW), Stomatology Hospital (CN), Sun Yat-sen University Cancer Center (CN), Ministry of Education (ET), First Affiliated Hospital of Soochow University (CN), Olivia Newton-John Cancer Wellness & Research Centre (AU), National Guard Health Affairs (SA), Monash University (AU), Alexandria University (EG), Sungkyunkwan University (KR)
Partnerships for the goals
Openalex Percentile: Top 20%
Lymphoma Diagnosis and Treatment
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.